Familial combined hyperlipidaemia: Under-defined and under-diagnosed?

Current Vascular Pharmacology

Volumn 6, Issue 1, 2008, Pages 13-22

  Wierzbicki, Anthony S ^a   Graham, Colin A ^b   Young, Ian S ^c   Nicholls, D Paul ^d  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b BELFAST CITY HOSPITAL   (United Kingdom)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

Colesterol; Familial combined hyperlipidaemia; Genetics; Insulin resistance; Triglyceride

Indexed keywords

APOLIPOPROTEIN A5; GENE PRODUCT; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PROTEIN CD36; STEROLIN 1; STEROLIN 2; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UPSTREAM STIMULATORY FACTOR 1; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL MODEL; CHROMOSOME 11; CHROMOSOME 1Q; CHROMOSOME 4; DISEASE ASSOCIATION; DISEASE MODEL; EXPERIMENTAL RABBIT; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILIAL HYPERLIPEMIA; GENE FUNCTION; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; HCB 19/DEM MOUSE; HERITABILITY; HUMAN; HYPERTENSION; INHERITANCE; ISCHEMIC HEART DISEASE; MOUSE; MOUSE STRAIN; NONHUMAN; POPULATION GENETICS; PREVALENCE; QUANTITATIVE TRAIT LOCUS MAPPING; RAT; REVIEW; SAINT THOMAS RABBIT; SINGLE NUCLEOTIDE POLYMORPHISM; SPONTANEOUSLY HYPERTENSIVE RAT; STROKE PRONE SPONTANEOUSLY HYPERTENSIVE RAT; ANIMAL; GENETICS; NOMENCLATURE;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; TERMINOLOGY AS TOPIC;

EID: 43249113169     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016108783331268     Document Type: Review

References (111)

1. Sniderman AD, Castro CM, Ribalta J, Carmena R, de Bruin TW, de GJ, et al. A proposal to redefine familial combined hyperlipidaemia - third workshop on FCHL held in Barcelona from 3 to 5 May 2001, during the scientific sessions of the European Society for Clinical Investigation. Eur J Clin Invest 2002; 32(2): 71-73.
2. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973; 52(7): 1544-1568.
3. Chen W, Srinivasan SR, Bao W, Wattigney WA., Berenson GS. The relationship of conjoint traits of dyslipidemias between young offspring and their parents in a community-based sample. Prev Med 1997; 26(5 Pt 1): 717-723.
4. Iwata F, Okada T, Kuromori Y, Hara M, Harada K. Screening for familial combined hyperlipidemia in children using lipid phenotypes. J Atheroscler Thromb 2003; 10(5): 299-303.
5. Cortner JA, Coates PM, Gallagher PR. Prevalence and expression of familial combined hyperlipidemia in childhood. J Pediatr 1990; 116(4): 514-519.
6. Gaddi A, Cicero AFG, Dormi A, Bove M. Estimation of familial combined hyperlipoproteinemia prevalence in a South-European population: the Brisighella heart study (BHS). 7 ed. 2006. p. 50.
7. Castro CM, Erkelens DW, Kock LA, de Bruin TW. Postprandial apolipoprotein B100 and B48 metabolism in familial combined hyperlipidaemia before and after reduction of fasting plasma triglycerides. Eur J Clin Invest 1994; 24(10): 669-678.
8. van Barlingen HH, Kock LA, De Man FH, Erkelens DW, de Bruin TW. In vitro lipolysis of human VLDL: effect of different VLDL compositions in normolipidemia, familial combined hyperlipidemia and familial hypertriglyceridemia. Atherosclerosis 1996; 121(1): 75-84.
9. Castro CM, de Bruin TW, de Valk HW, Shoulders CC, Jansen H, Willem ED. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J Clin Invest 1993; 92(1): 160-168.
10. Meijssen S, van DH, Verseyden C, Erkelens DW, Cabezas MC. Delayed and exaggerated postprandial complement component 3 response in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2002; 22(5): 811-816.
11. Chait A, Albers JJ, Brunzell JD. Very low density lipoprotein overproduction in genetic forms of hypertriglyceridaemia. Eur J Clin Invest 1980; 10(1): 17-22.
12. Verseyden C, Meijssen S, Castro CM. Postprandial changes of apoB-100 and apoB-48 in TG rich lipoproteins in familial combined hyperlipidemia. J Lipid Res 2002; 43(2): 274-280.
13. Sane T, Nikkila EA. Very low density lipoprotein triglyceride metabolism in relatives of hypertriglyceridemic probands. Evidence for genetic control of triglyceride removal. Arteriosclerosis 1988; 8(3): 217-226.
14. Ascaso JF, Merchante A, Lorente RI, Real JT, Martinez-Valls J, Carmena R. A study of insulin resistance using the minimal model in nondiabetic familial combined hyperlipidemic patients. Metabolism 1998; 47(5): 508-513.
15. Georgieva AM, Van Greevenbroek MM, Krauss RM, Brouwers MC, Vermeulen VM, Robertus-Teunissen MG, et al. Subclasses of low-density lipoprotein and very low-density lipoprotein in familial combined hyperlipidemia: relationship to multiple lipoprotein phenotype. Arterioscler Thromb Vasc Biol 2004; 24(4): 744-749.
16. Ascaso JF, Real JT, Merchante A, Rodrigo A, Carmena R. Lipoprotein phenotype and insulin resistance in familial combined hyperlipidemia. Metabolism 2000; 49(12): 1627-1631.
17. de Bruin TW, Georgieva AM, Brouwers MC, Heitink MV, van der Kallen CJ, Van Greevenbroek MM. Radiological evidence of non-alcoholic fatty liver disease in familial combined hyperlipidemia. Am J Med 2004; 116(12): 847-849.
18. Pihlajamaki J, Austin M, Edwards K, Laakso M. A major gene effect on fasting insulin and insulin sensitivity in familial combined hyperlipidemia. Diabetes 2001; 50(10): 2396-2401.
19. de Graaf J, Veerkamp MJ, Stalenhoef AF. Metabolic pathogenesis of familial combined hyperlipidaemia with emphasis on insulin resistance, adipose tissue metabolism and free fatty acids. J R Soc Med 2002; 95 Suppl 42: 46-53.
20. Veerkamp MJ, de Graaf J, Stalenhoef AF. Role of insulin resistance in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2005; 25(5): 1026-1031.
21. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 1991; 303(6807): 893-896.
22. Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003; 168(1): 1-14.
23. Graham CA, McClean E, Ward AJ, Beattie ED, Martin S, O'Kane M, et al. Mutation screening and genotype:phenotype correlation in familial hypercholesterolaemia. Atherosclerosis 1999; 147(2): 309-316.
24. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34(2): 154-156.
25. Primatesta P, Poulter NR. Lipid levels and the use of lipid-lowering agents in England and Scotland. Eur J Cardiovasc Prev Rehabil 2004; 11(6): 484-488.
26. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364(9438): 937-952.
27. Yu Y, Wyszynski DF, Waterworth DM, Wilton SD, Barter PJ, Kesaniemi YA, et al. Multiple QTLs influencing triglyceride and HDL and total cholesterol levels identified in families with atherogenic dyslipidemia. J Lipid Res 2005; 46(10):2 202-2213.
28. Shoulders CC, Jones EL, Naoumova RP. Genetics of familial combined hyperlipidemia and risk of coronary heart disease. Hum Mol Genet 2004; 13 Spec No 1: R149-R160.
29. Austin MA, McKnight B, Edwards KL, Bradley CM, McNeely MJ, Psaty BM, et al. Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study. Circulation 2000; 101(24): 2777-2782.
30. Williams RR, Hunt SC, Hopkins PN, Stults BM, Wu LL, Hasstedt SJ, et al. Familial dyslipidemic hypertension. Evidence from 58 Utah families for a syndrome present in approximately 12% of patients with essential hypertension. JAMA 1988; 259(24): 3579-3586.
31. Williams RR, Hunt SC, Hopkins PN, Wu LL, Hasstedt SJ, Berry TD, et al. Genetic basis of familial dyslipidemia and hypertension: 15-year results from Utah. Am J Hypertens 1993; 6(11 Pt 2): 319S-327S.
32. Veerkamp MJ, de GJ, Hendriks JC, Demacker PN, Stalenhoef AF. Nomogram to diagnose familial combined hyperlipidemia on the basis of results of a 5-year follow-up study. Circulation 2004; 109(24): 2980-2985.
33. Keulen ET, Voors-Pette C, de Bruin TW. Familial dyslipidemic hypertension syndrome: familial combined hyperlipidemia, and the role of abdominal fat mass. Am J Hypertens 2001; 14(4 Pt 1): 357-363.
34. Hardman TC, Lant AF. Controversies surrounding erythrocyte sodium-lithium countertransport. J Hypertens 1996; 14(6): 695-703.
35. Williams RR, Hunt SC, Kuida H, Smith JB, Ash KO. Sodium-lithium countertransport in erythrocytes of hypertension prone families in Utah. Am J Epidemiol 1983; 118(3): 338-344.
36. Hasstedt SJ, Wu LL, Ash KO, Kuida H, Williams RR. Hypertension and sodium-lithium countertransport in Utah pedigrees: evidence for major-locus inheritance. Am J Hum Genet 1988; 43(1): 14-22.
37. Rebbeck TR, Turner ST, Michels VV, Moll PP. Genetic and environmental explanations for the distribution of sodium- lithium countertransport in pedigrees from Rochester, MN. Am J Hum Genet 1991; 48(6): 1092-1104.
38. Turner ST, Michels VV. Sodium-lithium countertransport and hypertension in Rochester, Minnesota. Hypertension 1991; 18(2): 183-190.
39. Thomas TH, Rutherford PA, West IC, Wilkinson R. Sulphydryl group control of sodium-lithium countertransport kinetics: a membrane protein control abnormality in essential hypertension. Eur J Clin Invest 1995 Apr; 25(4): 235-240.
40. Weder AB, Schork NJ, Julius S. Linkage of MN locus and erythrocyte lithium-sodium countertransport in Tecumseh, Michigan. Hypertension 1991; 17(6 Pt 2): 977-981.
41. Hasstedt SJ, Camp NJ, Hopkins PN, Coon H, McKinney JT, Cawthon PM, et al. Model-fitting and linkage analysis of sodium-lithium countertransport. Eur J Hum Genet 2004; 12(12): 1055-1061.
42. Morrison AC, Boerwinkle E, Turner ST, Ferrell RE. Genome-wide linkage study of erythrocyte sodium-lithium countertransport. Am J Hypertens 2005; 18(5 Pt 1): 653-656.
43. Weder AB, Delgado MC, Zhu X, Gleiberman L, Kan D, Chakravarti A. Erythrocyte sodium-lithium countertransport and blood pressure: a genome-wide linkage study. Hypertension 2003; 41(3 Pt 2): 842-846.
44. de Roos B, Caslake MJ, Ardern HA, Martin BG, Suckling KE, Packard CJ. Insulin resistance in the St. Thomas' mixed hyperlipidaemic (SMHL) rabbit, a model for familial combined hyperlipidaemia. Atherosclerosis 2001; 156(2): 249-254.
45. de Roos B, Caslake MJ, Milliner K, Benson GM, Suckling KE, Packard CJ. Characterisation of the lipoprotein structure in the St. Thomas' Mixed Hyperlipidaemic (SMHL) rabbit. Atherosclerosis 2005; 181(1): 63-68.
46. Masucci-Magoulas L, Goldberg IJ, Bisgaier CL, Serajuddin H, Francone OL, Breslow JL, et al. A mouse model with features of familial combined hyperlipidemia. Science 1997; 275(5298): 391-394.
47. Van Greevenbroek MM, Vermeulen VM, de Bruin TW. Identification of novel molecular candidates for fatty liver in the hyperlipidemic mouse model, HcB19. J Lipid Res 2004; 45(6): 1148-1154.
48. Bodnar JS, Chatterjee A, Castellani LW, Ross DA, Ohmen J, Cavalcoli J, et al. Positional cloning of the combined hyperlipidemia gene Hyplip1. Nat Genet 2002; 30(1): 110-116.
49. Ueno T, Tremblay J, Kunes J, Zicha J, Dobesova Z, Pausova Z, et al. Rat model of familial combined hyperlipidemia as a result of comparative mapping. Physiol Genomics 2004; 17(1): 38-47.
50. Aitman TJ, Pravenec M, Kurtz TW, Scott J. The spontaneously hypertensive rat: a model to dissect cellular defects in glucose and fatty acid metabolism. Pathol Biol (Paris) 1998; 46(9): 693-694.
51. Monti J, Zimdahl H, Schulz H, Plehm R, Ganten D, Hubner N. The role of Wnk4 in polygenic hypertension: a candidate gene analysis on rat chromosome 10. Hypertension 2003; 41(4): 938-942.
52. Pravenec M, Jansa P, Kostka V, Zidek V, Kren V, Forejt J, et al. Identification of a mutation in ADD1/SREBP-1 in the spontaneously hypertensive rat. Mamm Genome 2001; 12(4): 295-298.
53. Scoggan KA, Gruber H, Lariviere K. A missense mutation in the Abcg5 gene causes phytosterolemia in SHR, stroke-prone SHR, and WKY rats. J Lipid Res 2003; 44(5): 911-916.
54. Lu K, Lee MH, Hazard S, Brooks-Wilson A, Hidaka H, Kojima H, et al. Two genes that map to the STSL locus cause sitosterolemia: genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively. Am J Hum Genet 2001; 69(2): 278-290.
55. Klett EL, Lu K, Kosters A, Vink E, Lee MH, Altenburg M, et al. A mouse model of sitosterolemia: absence of Abcg8/sterolin-2 results in failure to secrete biliary cholesterol. BMC Med 2004; 2: 5.
56. Berge KE, Tian H, Graf GA, Yu L, Grishin NV, Schultz J, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 2000; 290(5497): 1771-1775.
57. Wang J, Joy T, Mymin D, Frohlich J, Hegele RA. Phenotypic heterogeneity of sitosterolemia. J Lipid Res 2004; 45(12): 2361-2367.
58. Ayyobi AF, McGladdery SH, McNeely MJ, Austin MA, Motulsky AG, Brunzell JD. Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2003; 23(7): 1289-1294.
59. Sijbrands EJ, Westendorp RG, Hoffer MJ, Havekes LM, Frants RR, Meinders AE, et al. Effect of insulin resistance, apoE2 allele, and smoking on combined hyperlipidemia. Arterioscler Thromb 1994; 14(10): 1576-1580.
60. Reiber I, Mezo I, Kalina A, Palos G, Romics L, Csaszar A. Post-prandial triglyceride levels in familial combined hyperlipidemia. The role of apolipoprotein E and lipoprotein lipase polymorphisms. J Nutr Biochem 2003 Jul; 14(7): 394-400.
61. Deeb SS, Nevin DN, Iwasaki L, Brunzell JD. Two novel apolipoprotein A-IV variants in individuals with familial combined hyperlipidemia and diminished levels of lipoprotein lipase activity. Hum Mutat 1996; 8(4): 319-325.
62. Pihlajamaki J, Karjalainen L, Karhapaa P, Vauhkonen I, Taskinen MR, Deeb SS, et al. G-250A substitution in promoter of hepatic lipase gene is associated with dyslipidemia and insulin resistance in healthy control subjects and in members of families with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2000; 20(7): 1789-1795.
63. Marcil M, Boucher B, Gagne E, Davignon J, Hayden M, Genest J, Jr. Lack of association of the apolipoprotein A-I-C-III-A-IV gene XmnI and SstI polymorphisms and of the lipoprotein lipase gene mutations in familial combined hyperlipoproteinemia in French Canadian subjects. J Lipid Res 1996; 37(2): 309-319.
64. Pajukanta P, Porkka KV, Antikainen M, Taskinen MR, Perola M, Murtomaki-Repo S, et al. No evidence of linkage between familial combined hyperlipidemia and genes encoding lipolytic enzymes in Finnish families. Arterioscler Thromb Vasc Biol 1997; 17(5): 841-850.
65. Salazar J, Ferre R, Vallve JC, Pocovi M, Cabezas MC, Masana L, et al. Two novel single nucleotide polymorphisms in the promoter of the cellular retinoic acid binding protein II gene (CRABP-II). Mol Cell Probes 2003; 17(1): 21-23.
66. Riddle TM, Kuhel DG, Woollett LA, Fichtenbaum CJ, Hui DY. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem 2001; 276(40): 37514-37519.
67. Tybjaerg-Hansen A, Nordestgaard BG, Gerdes LU, Faergeman O, Humphries SE. Genetic markers in the apo AI-CIII-AIV gene cluster for combined hyperlipidemia, hypertriglyceridemia, and predisposition to atherosclerosis. Atherosclerosis 1993;100(2): 157-169.
68. Wijsman EM, Brunzell JD, Jarvik GP, Austin MA, Motulsky AG, Deeb SS. Evidence against linkage of familial combined hyperlipidemia to the apolipoprotein AI-CIII-AIV gene complex. Arterioscler Thromb Vasc Biol 1998; 18(2): 215-226.
69. Tahvanainen E, Pajukanta P, Porkka K, Nieminen S, Ikavalko L, Nuotio I, et al. Haplotypes of the ApoA-I/C-III/A-IV gene cluster and familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1998; 18(11): 1810-1817.
70. Dallinga-Thie GM, van Linde-Sibenius TM, Rotter JI, Cantor RM, Bu X, Lusis AJ, et al. Complex genetic contribution of the Apo AI-CIII-AIV gene cluster to familial combined hyperlipidemia. Identification of different susceptibility haplotypes. J Clin Invest 1997; 99(5): 953-961.
71. Eichenbaum-Voline S, Olivier M, Jones EL, Naoumova RP, Jones B, Gau B, et al. Linkage and association between distinct variants of the APOA1/C3/A4/A5 gene cluster and familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2004; 24(1): 167-174.
72. Mar R, Pajukanta P, Allayee H, Groenendijk M, linga-Thie G, Krauss RM, et al. Association of the APOLIPOPROTEIN A1/C3/A4/A5 gene cluster with triglyceride levels and LDL particle size in familial combined hyperlipidemia. Circ Res 2004; 94(7): 993-999.
73. Chan DC, Watts GF, Nguyen MN, Barrett PH. Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics. Arterioscler Thromb Vasc Biol 2006; 26(3): 590-596.
74. Calandra S, Oliva CP, Tarugi P, Bertolini S. APOA5 and triglyceride metabolism, lesson from human APOA5 deficiency. Curr Opin Lipidol 2006; 17(2): 122-127.
75. Wright WT, Young IS, Nicholls DP, Patterson C, Lyttle K, Graham CA. SNPs at the APOA5 gene account for the strong association with hypertriglyceridaemia at the APOA5/A4/C3/A1 locus on chromosome 11q23 in the Northern Irish population. Atherosclerosis 2006; 185(2): 353-360.
76. Cantor RM, de BT, Kono N, Napier S, van NA, Allayee H, et al. Quantitative trait loci for apolipoprotein B, cholesterol, and triglycerides in familial combined hyperlipidemia pedigrees. Arterioscler Thromb Vasc Biol 2004; 24(10): 1935-1941.
77. Cohen JC, Boerwinkle E, Mosley TH, Hobbs RH. Sequence variations in PCSK-9, low LDL and protection against coronary heart disease. N Engl J Med 2006; 354(12): 1264-1272.
78. Chen SN, Ballantyne CM, Gotto AM, Jr., Tan Y, Willerson JT, Marian AJ. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol 2005; 45(10): 1611-1619.
79. McNeely MJ, Edwards KL, Marcovina SM, Brunzell JD, Motulsky AG, Austin MA. Lipoprotein and apolipoprotein abnormalities in familial combined hyperlipidemia: a 20-year prospective study. Atherosclerosis 2001; 159(2): 471-481.
80. Coon H, Myers RH, Borecki IB. Arnett DK, Hunt SC, Province MA, et al. Replication of linkage of familial combined hyperlipidemia to chromosome 1q with additional heterogeneous effect of apolipoprotein A-I/ C-III/A-IV locus. The NHLBI Family Heart Study. Arterioscler Thromb Vasc Biol 2000; 20(10): 2275-2280.
81. Pajukanta P, Bodnar JS, Sallinen R, Chu M, Airaksinen T, Xiao Q, et al. Fine mapping of Hyplip1 and the human homolog, a potential locus for FCHL. Mamm Genome 2001; 12(3): 238-245.
82. Naukkarinen J, Gentile M, Soro-Paavonen A, Saarela J, Koistinen HA, Pajukanta P, et al. USF1 and dyslipidemias: converging evidence for a functional intronic variant. Hum Mol Genet 2005; 14(17): 2595-2605.
83. Coon H, Singh N, Dunn D, Eckfeldt JH, Province MA, Hopkins PN, et al. TXNIP gene not associated with familial combined hyperlipidemia in the NHLBI Family Heart Study. Atherosclerosis 2004; 174(2): 357-362.
84. Wang X, Gargalovic P, Wong J, Gu JL, Wu X, Qi H, et al. Hyplip2, a new gene for combined hyperlipidemia and increased atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24(10): 1928-1934.
85. Ylitalo K, Pajukanta P, Meri S, Cantor RM, Mero-Matikainen N, Vakkilainen J, et al. Serum C3 but not plasma acylation-stimulating protein is elevated in Finnish patients with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2001; 21(5): 838-843.
86. Aouizerat BE, Allayee H, Cantor RM, Davis RC, Lanning CD, Wen PZ, et al. A genome scan for familial combined hyperlipidemia reveals evidence of linkage with a locus on chromosome 11. Am J Hum Genet 1999; 65(2): 397-412.
87. Naoumova RP, Bonney SA, Eichenbaum-Voline S, Patel HN, Jones B, Jones EL, et al. Confirmed locus on chromosome 11p and candidate loci on 6q and 8p for the triglyceride and cholesterol traits of combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2003; 23(11): 2070-2077.
88. Wyszynski DF, Waterworth DM, Barter PJ, Cohen J, Kesaniemi YA, Mabley RW, et al. Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project). Am J Cardiol 2005; 95(2): 194-198.
89. Pajukanta P, Nuotio I, Terwilliger JD, Porkka KV, Ylitalo K, Pihlajamaki J, et al. Linkage of familial combined hyperlipidaemia to chromosome 1q21-q23. Nat Genet 1998; 18(4): 369-373.
90. Lee JC, Lusis AJ, Pajukanta P. Familial combined hyperlipidemia: upstream transcription factor 1 and beyond. Curr Opin Lipidol 2006; 17(2): 101-109.
91. Pajukanta P, Lilja HE, Sinsheimer JS, Cantor RM, Lusis AJ, Gentile M, et al. Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat Genet 2004; 36(4): 371-376.
92. Coon H, Xin Y, Hopkins PN, Cawthon RM, Hasstedt SJ, Hunt SC. Upstream stimulatory factor 1 associated with familial combined hyperlipidemia, LDL cholesterol, and triglycerides. Hum Genet 2005; 117(5): 444-451.
93. Putt W, Palmen J, Nicaud V, Tregouet DA, Tahri-Daizadeh N, Flavell DM, et al. Variation in USF1 shows haplotype effects, gene: gene and gene: environment associations with glucose and lipid parameters in the European Atherosclerosis Research Study II. Hum Mol Genet 2004; 13(15): 1587-1597.
94. Huertas-Vazquez A, Guilar-Salinas C, Lusis AJ, Cantor RM, Canizales-Quinteros S, Lee JC, et al. Familial combined hyperlipidemia in Mexicans: association with upstream transcription factor 1 and linkage on chromosome 16q24.1. Arterioscler Thromb Vasc Biol 2005; 25(9): 1985-1991.
95. Gibson F, Hercberg S, Froguel P. Common polymorphisms in the USF1 gene are not associated with type 2 diabetes in French Caucasians. Diabetes 2005; 54(10): 3040-3042.
96. Ng MC, Miyake K, So WY, Poon EW, Lam VK, Li JK, et al. The linkage and association of the gene encoding upstream stimulatory factor 1 with type 2 diabetes and metabolic syndrome in the Chinese population. Diabetologia 2005; 48(10): 2018-2024.
97. Kammerer CM, Cox LA, Mahaney MC, Rogers J, Shade RE. Sodium-lithium countertransport activity is linked to chromosome 5 in baboons. Hypertension 2001; 37(2 Part 2): 398-402.
98. Aitman TJ. CD36, insulin resistance, and coronary heart disease. Lancet 2001; 357(9257): 651-652.
99. Pearson ER, Pruhova S, Tack CJ, Johansen A, Castleden HA, Lumb PJ, et al. Molecular genetics and phenotypic characteristics of MODY caused by hepatocyte nuclear factor 4alpha mutations in a large European collection. Diabetologia 2005; 48(5): 878-885.
100. Weissglas-Volkov D, Huertas-Vazquez A, Suviolahti E, Lee J, Plaisier C, Canizales-Quinteros S, et al. Common Hepatic Nuclear Factor-4{alpha} Variants Are Associated With High Serum Lipid Levels and the Metabolic Syndrome. Diabetes 2006; 55(7): 1970-1977.
101. Soro A, Pajukanta P, Lilja HE, Ylitalo K, Hiekkalinna T, Perola M, et al. Genome scans provide evidence for low-HDL-C loci on chromosomes 8q23, 16q24.1-24.2, and 20q13.11 in Finnish families. Am J Hum Genet 2002; 70(5): 1333-1340.
102. Meex SJ, van der Kallen CJ, Van Greevenbroek MM, Eurlings PM, EL HM, Evelo CT, et al. Up-regulation of CD36/FAT in preadipocytes in familial combined hyperlipidemia. FASEB J 2005; 19(14): 2063-2065.
103. Aitman TJ, Cooper LD, Norsworthy PJ, Wahid FN, Gray JK, Curtis BR, et al. Malaria susceptibility and CD36 mutation. Nature 2000; 405(6790): 1015-1016.
104. Brunzell JD, Albers JJ, Chait A, Grundy SM, Groszek E, McDonald GB. Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res 1983; 24(2): 147-155.
105. Pajukanta P, Terwilliger JD, Perola M, Hiekkalinna T, Nuotio I, Ellonen P, et al. Genomewide scan for familial combined hyperlipidemia genes in finnish families, suggesting multiple susceptibility loci influencing triglyceride, cholesterol, and apolipoprotein B levels. Am J Hum Genet 1999; 64(5): 1453-1463.
106. Huertas-Vazquez A, del Rincon JP, Canizales-Quinteros S, Riba L, Vega-Hernandez G, Ramirez-Jimenez S, et al. Contribution of chromosome 1q21-q23 to familial combined hyperlipidemia in Mexican families. Ann Hum Genet 2004; 68(Pt 5): 419-427.
107. Pajukanta P, Allayee H, Krass KL, Kuraishy A, Soro A, Lilja HE, et al. Combined analysis of genome scans of dutch and finnish families reveals a susceptibility locus for high-density lipoprotein cholesterol on chromosome 16q. Am J Hum Genet 2003; 72(4): 903-917.
108. Pei W, Baron H, Muller-Myhsok B, Knoblauch H, Al-Yahyaee SA, Hui R, et al. Support for linkage of familial combined hyperlipidemia to chromosome 1q21-q23 in Chinese and German families. Clin Genet 2000; 57(1): 29-34.
109. Allayee H, Castellani LW, Cantor RM, de Bruin TW, Lusis AJ. Biochemical and genetic association of plasma apolipoprotein A-II levels with familial combined hyperlipidemia. Circ Res 2003; 92(11): 1262-1267.
110. Allayee H, Krass KL, Pajukanta P, Cantor RM, van der Kallen CJ, Mar R, et al. Locus for elevated apolipoprotein B levels on chromosome 1p31 in families with familial combined hyperlipidemia. Circ Res 2002; 90(8): 926-931.
111. Allayee H, de Bruin TW, Michelle DK, Cheng LS, Ipp E, Cantor RM, et al. Genome scan for blood pressure in Dutch dyslipidemic families reveals linkage to a locus on chromosome 4p. Hypertension 2001; 38(4): 773-778.